ITM1098
ITM1098
ITM1098
from
$556.00
Price in reward points: 556
- Catalog: ITM1098
- Gene/Protein: SOCS3
- Product Description: Immunotag™ SOCS-3 Monoclonal Antibody
-
Description
-
Specifications
Antibody Specification Datasheet 
IMPORTANT NOTE This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return. Target Protein SOCS3 Clonality Monoclonal Storage/Stability -20°C/1 year Application WB,IHC-p Recommended Dilution Western Blot: 1/1000 - 1/2000. Immunohistochemistry: 1/500 - 1/1000. Not yet tested in other applications. Concentration 1 mg/ml Reactive Species Human Host Species Mouse Immunogen Purified recombinant human SOCS-3 (N-terminus) protein fragments expressed in E.coli. Specificity SOCS-3 Monoclonal Antibody detects endogenous levels of SOCS-3 protein. Purification Affinity purification Form Purified mouse monoclonal in buffer containing 0.1M Tris-Glycine (pH 7.4, 150 mM NaCl) with 0.2% sodium azide, 50% glycerol. Gene Name SOCS3 Accession No. O14543 O35718 Alternate Names SOCS3; CIS3; SSI3; Suppressor of cytokine signaling 3; SOCS-3; Cytokine-inducible SH2 protein 3; CIS-3; STAT-induced STAT inhibitor 3; SSI-3 Description suppressor of cytokine signaling 3(SOCS3) Homo sapiens This gene encodes a member of the STAT-induced STAT inhibitor (SSI), also known as suppressor of cytokine signaling (SOCS), family. SSI family members are cytokine-inducible negative regulators of cytokine signaling. The expression of this gene is induced by various cytokines, including IL6, IL10, and interferon (IFN)-gamma. The protein encoded by this gene can bind to JAK2 kinase, and inhibit the activity of JAK2 kinase. Studies of the mouse counterpart of this gene suggested the roles of this gene in the negative regulation of fetal liver hematopoiesis, and placental development. [provided by RefSeq, Jul 2008], Cell Pathway/ Category Ubiquitin mediated proteolysis,Jak_STAT,Insulin_Receptor,Adipocytokine,Type II diabetes mellitus, Protein Expression Placenta,Skeletal muscle,T-cell lymphoma,Thymus, Subcellular Localization intracellular,cytoplasm,cytosol, Protein Function disease:Genetic variation in the promoter region of SOCS3 may be associated with susceptibility to atopic dermatitis 4 (ATOD4) [MIM:605805]. Atopic dermatitis [MIM:603165], also known as eczema commonly begins in infancy or early childhook and is characterized by ichy and inflamed skin.,domain:The ESS and SH2 domains are required for JAK phosphotyrosine binding. Further interaction with the KIR domain is necessary for signal and kinase inhibition.,domain:The SOCS box domain mediates the interaction with the Elongin BC complex, an adapter module in different E3 ubiquitin ligase complexes.,function:SOCS family proteins form part of a classical negative feedback system that regulates cytokine signal transduction. SOCS3 is involved in negative regulation of cytokines that signal through the JAK/STAT pathway. Inhibits cytokine signal transduction by binding to tyrosine kinase receptors including gp130, LIF, erythropoietin, insulin, IL12, GCSF and leptin receptors. Binding to JAK2 inhibits its kinase activity. Suppresses fetal liver erythropoiesis. Regulates onset and maintenance of allergic responses mediated by T-helper type 2 cells. Regulates IL-6 signaling in vivo (By similarity). Probable substrate recognition component of a SCF-like ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Seems to recognize IL6ST.,pathway:Protein modification; protein ubiquitination.,pharmaceutical:SOCS3 could be used as a possible therapeutic agent for treating rheumatoid arthritis.,PTM:Phosphorylated on tyrosine residues after stimulation by the cytokines, IL-2, EPO or IGF1.,similarity:Contains 1 SH2 domain.,similarity:Contains 1 SOCS box domain.,subunit:Interacts with multiple activated proteins of the tyrosine kinase signaling pathway including IGF1 receptor, insulin receptor and JAK2. Binding to JAK2 is mediated through the KIR and SH2 domains to a phosphorylated tyrosine residue within the JAK2 JH1 domain. Binds specific activated tyrosine residues of the leptin, EPO, IL12, GSCF and gp130 receptors. Interaction with CSNK1E stabilizes SOCS3 protein. Component of the probable ECS(SOCS3) E3 ubiquitin-protein ligase complex which contains CUL5, RNF7/RBX2, Elongin BC complex and SOCS3. Interacts with CUL5, RNF7, TCEB1 and TCEB2. Interacts with CUL2.,tissue specificity:Widely expressed with high expression in heart, placenta, skeletal muscle, peripheral blood leukocytes, fetal and adult lung, and fetal liver and kidney. Lower levels in thymus., Usage For Research Use Only! Not for diagnostic or therapeutic procedures. - Reviews
| Antibody Specification | |
| Datasheet | |
| IMPORTANT NOTE | This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return. |
| Target Protein | SOCS3 |
| Clonality | Monoclonal |
| Storage/Stability | -20°C/1 year |
| Application | WB,IHC-p |
| Recommended Dilution | Western Blot: 1/1000 - 1/2000. Immunohistochemistry: 1/500 - 1/1000. Not yet tested in other applications. |
| Concentration | 1 mg/ml |
| Reactive Species | Human |
| Host Species | Mouse |
| Immunogen | Purified recombinant human SOCS-3 (N-terminus) protein fragments expressed in E.coli. |
| Specificity | SOCS-3 Monoclonal Antibody detects endogenous levels of SOCS-3 protein. |
| Purification | Affinity purification |
| Form | Purified mouse monoclonal in buffer containing 0.1M Tris-Glycine (pH 7.4, 150 mM NaCl) with 0.2% sodium azide, 50% glycerol. |
| Gene Name | SOCS3 |
| Accession No. | O14543 O35718 |
| Alternate Names | SOCS3; CIS3; SSI3; Suppressor of cytokine signaling 3; SOCS-3; Cytokine-inducible SH2 protein 3; CIS-3; STAT-induced STAT inhibitor 3; SSI-3 |
| Description | suppressor of cytokine signaling 3(SOCS3) Homo sapiens This gene encodes a member of the STAT-induced STAT inhibitor (SSI), also known as suppressor of cytokine signaling (SOCS), family. SSI family members are cytokine-inducible negative regulators of cytokine signaling. The expression of this gene is induced by various cytokines, including IL6, IL10, and interferon (IFN)-gamma. The protein encoded by this gene can bind to JAK2 kinase, and inhibit the activity of JAK2 kinase. Studies of the mouse counterpart of this gene suggested the roles of this gene in the negative regulation of fetal liver hematopoiesis, and placental development. [provided by RefSeq, Jul 2008], |
| Cell Pathway/ Category | Ubiquitin mediated proteolysis,Jak_STAT,Insulin_Receptor,Adipocytokine,Type II diabetes mellitus, |
| Protein Expression | Placenta,Skeletal muscle,T-cell lymphoma,Thymus, |
| Subcellular Localization | intracellular,cytoplasm,cytosol, |
| Protein Function | disease:Genetic variation in the promoter region of SOCS3 may be associated with susceptibility to atopic dermatitis 4 (ATOD4) [MIM:605805]. Atopic dermatitis [MIM:603165], also known as eczema commonly begins in infancy or early childhook and is characterized by ichy and inflamed skin.,domain:The ESS and SH2 domains are required for JAK phosphotyrosine binding. Further interaction with the KIR domain is necessary for signal and kinase inhibition.,domain:The SOCS box domain mediates the interaction with the Elongin BC complex, an adapter module in different E3 ubiquitin ligase complexes.,function:SOCS family proteins form part of a classical negative feedback system that regulates cytokine signal transduction. SOCS3 is involved in negative regulation of cytokines that signal through the JAK/STAT pathway. Inhibits cytokine signal transduction by binding to tyrosine kinase receptors including gp130, LIF, erythropoietin, insulin, IL12, GCSF and leptin receptors. Binding to JAK2 inhibits its kinase activity. Suppresses fetal liver erythropoiesis. Regulates onset and maintenance of allergic responses mediated by T-helper type 2 cells. Regulates IL-6 signaling in vivo (By similarity). Probable substrate recognition component of a SCF-like ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Seems to recognize IL6ST.,pathway:Protein modification; protein ubiquitination.,pharmaceutical:SOCS3 could be used as a possible therapeutic agent for treating rheumatoid arthritis.,PTM:Phosphorylated on tyrosine residues after stimulation by the cytokines, IL-2, EPO or IGF1.,similarity:Contains 1 SH2 domain.,similarity:Contains 1 SOCS box domain.,subunit:Interacts with multiple activated proteins of the tyrosine kinase signaling pathway including IGF1 receptor, insulin receptor and JAK2. Binding to JAK2 is mediated through the KIR and SH2 domains to a phosphorylated tyrosine residue within the JAK2 JH1 domain. Binds specific activated tyrosine residues of the leptin, EPO, IL12, GSCF and gp130 receptors. Interaction with CSNK1E stabilizes SOCS3 protein. Component of the probable ECS(SOCS3) E3 ubiquitin-protein ligase complex which contains CUL5, RNF7/RBX2, Elongin BC complex and SOCS3. Interacts with CUL5, RNF7, TCEB1 and TCEB2. Interacts with CUL2.,tissue specificity:Widely expressed with high expression in heart, placenta, skeletal muscle, peripheral blood leukocytes, fetal and adult lung, and fetal liver and kidney. Lower levels in thymus., |
| Usage | For Research Use Only! Not for diagnostic or therapeutic procedures. |